| Background and objective : Atopic dermatitis(AD)is a chronic relapsing,inflammatory skin disease which related to heredity and immune response abnormalities.It’s often worse in the winter.It’s a major public health problem worldwide with a lifetime prevalence of 10-30% in children and 65% of them occur within 18 months.The main clinical manifestations are erythema,papules,scales,skin dry and severe itching in infants and young children,which often affect the quality of life and bring heavy psychological pressure to the family,therefore,the treatment is very important.At present,the first-line treatment is TCS.The aim of this research has three:First is confirmed to mild-moderate TCS is safe and effective,which for 3 months to 2 years old infant patients with mild-to-moderate AD.The second is to evaluate the improvement of the quality of life on Desonide Cream.Finally compared Desonide Cream with Hydrocortisone Butyrate Ointment efficacy and safety of the mild-to-moderate AD.Therefore,we comparison of desicrine Ointmentwith Hydrocortisone Butyrate Ointment for Treating of Atopic Dermatitis in Infancy:a randomized,open and parallel controlled trial.Methods:This study is a randomized,open,parallel and prospective study,42 cases of infants with mild and moderate AD were included in 3months-2 infants with IGA score 2-3,which was less than 15% of the body surface area,and were randomly assigned to the experimental group(Desonide Cream)and the control group(Hydrocortisone Butyrate Ointment).Two groups use the ointment in skin lesions twice daily,morning and evening,during 3 weeks follow-up if the IGA score less than 1 minute to use twice a week,Weekly follow-up should be observed the patient’s symptoms,eczema area,and EASI scores,IDLQI,itching index.During the treatment,all infants use the same brand emollient,and avoid other related external ointment.In addition,the objective evaluation of the effect according to curative effect index,which is base on EASI,more than 95% is healing.Results:In all 42 cases were brought into the research and 42 cases completed the study.The results were as follows,1.IGA:At the first visit,their respective values2.38±0.498、2.48±0.512(P>0.05),Day 7:1.10±0.301、1.05±0.4798(P>0.05),Day 14:0.62±0.740、0.67±0.730(P>0.05),Day 21:0.29±0.784、0.14±0.359(P>0.05),the three visits were significantly improved compared to the first,but there was no difference between the groups.2.EASI:At the first visit,their respectivevalues :1.99±0.978 V 1.76±1.405(P>0.05),Day 7:0.57±0.343 V 0.64±0.513(P>0.05),Day 14:0.29±0.604 V 0.34±0.590(P>0.05),Day21:0.19 ± 0.623 V 0.12 ± 0.325(P > 0.05),the three visits were significantly improved compared to the first,but there was no difference between the groups.3.Day7,the effective rate:80.95% V 71.43%(P >0.05);Day14:90.48% V 100.00%(P>0.05);Day21:90.48% V 100.00%(P>0.05).3.Both of the IDLQI and itch value were significantly improved after 3 weeks of treatment,and there was no significant difference between the test group and the control group(P > 0.05).4.In the entire course of treatment,there were 7 cases of adverse effect,2 cases in test group,the main were skin redness,agitated and recurrence,5 cases in the control group,including redness,agitated and hypopigmentation.Conclusion : 1.Desonide Cream and Hydrocortisone Butyrate Ointment were effective for mild to moderate AD treatment,and the effective time was comparable.2.Desonide Cream and Hydrocortisone Butyrate Ointment can improve the symptoms and itching of mild and moderate AD and the quality of life.3.Desonide Cream has less adverse effect than Hydrocortisone Butyrate Ointment,which is safe and effective. |
PDF Full Text Request